#None #antibody development #Genedata #Abcam

Collaborating for a Scientific Breakthrough

In an era defined by rapid advancements in biotechnology, Genedata, a pioneer in enterprise software for biopharmaceutical research and development (R&D), has announced an expanded collaboration with Abcam, a leader in validated antibodies and assay solutions. This partnership aims to reshape antibody development, leveraging both companies' expertise to harness the power of artificial intelligence (AI). By implementing the Genedata Biologics platform across Abcam's global R&D organization, the two companies strive to enhance data connectivity and promote innovation.

Shared Vision for Innovation

This strategic collaboration is particularly relevant as researchers increasingly seek high-quality antibodies for a diverse range of targets and applications. Kaveh Kahen, PhD, President of Abcam, highlighted the importance of scaling the company’s development capabilities to meet growing demands, stating that building upon Genedata's robust platform will provide the necessary automation, connectivity, and flexibility to support their global R&D efforts.

The integration of Genedata Biologics at Abcam's headquarters in the UK, along with key facilities in the United States and China, has laid the groundwork for a unified data structure that connects diverse teams worldwide. This enhanced connectivity enables improved consistency, visibility, and collaboration throughout the antibody development process, allowing Abcam to operate more efficiently while upholding the quality standards that researchers depend on.

Transforming Antibody Development

The implementation of Genedata Biologics serves as a digital backbone for Abcam's extensive antibody development pipeline, which is known for delivering around 500 new antibodies annually. The platform streamlines complex workflows, tracks sample histories, and captures invaluable antibody characterization data—all within a secure and organized environment. By consolidating data, processes, and teams, Abcam is now poised to advance promising candidates more rapidly, granting researchers quicker access to vital high-quality antibodies.

Genedata’s President, Othmar Pfannes, PhD, emphasized the shared commitment to using data and technology to drive scientific advancement. The combination of Abcam's extensive experience in antibody development with Genedata's cutting-edge platform creates an environment where scientific teams can work together more effectively. This partnership not only empowers teams to generate actionable insights at scale but also builds a solid foundation for AI-driven discovery. Ultimately, the researchers stand to benefit the most, gaining faster access to the validated reagents that are crucial for high-quality scientific outcomes.

About Genedata and Abcam

Genedata is a Danaher company specializing in enterprise-level software solutions designed to transform biopharmaceutical data into actionable intelligence. By merging profound scientific understanding with technology, Genedata assists professionals in digitalizing and automating intricate data workflows, thereby fostering innovation and maximizing return on investment (ROI). With over 25 years of service, the company boasts a trusted reputation among leading biopharma organizations and pioneering biotech firms.

On the other hand, Abcam, also a Danaher company, prides itself on accelerating research outcomes for the scientific community. It offers expert scientific support and highly validated antibodies and assays to assist 750,000 researchers across 130 countries. Their goal is to facilitate faster progress in critical areas such as cancer, neurological disorders, infectious diseases, and metabolic disorders.

The Path Ahead

As the partnership between Abcam and Genedata unfolds, there is a palpable excitement about the potential enhancements in antibody development capabilities. By integrating AI and unrivaled data connectivity into the workflow, these two innovators are set to transform how researchers access essential tools and reagents. This collaboration exemplifies the intersection of technology and scientific inquiry, posing a significant leap forward in the biopharmaceutical arena. The journey towards accelerating the delivery of high-quality antibodies has just begun, and researchers worldwide eagerly await the fruits of this remarkable collaboration.